Leuprolide

Introduction Overview

Generic Name

leuprolide

Brand Name

Camcevi, Eligard, Fensolvi, Lupron Depot, Lupron Depot-Ped, Lupron, Lupron Depot-Gyn, Viadur

Dosage Form

intramuscular injection, subcutaneous injection, subcutaneous implant, extended-release formulations, pediatric and adult dosing kits

Drug Class

Gonadotropin releasing hormones (GnRH) agonists; Hormones / antineoplastics

Pharmacokinetics

Absorption:
Leuprolide is administered parenterally due to poor oral bioavailability, most commonly via intramuscular or subcutaneous injection, or as a subcutaneous implant providing sustained drug release. Extended-release depot formulations enable slow and controlled absorption over periods ranging from one month up to six months, and implants can provide therapeutic drug levels for up to twelve months. Upon injection, the drug is gradually absorbed from the depot site into systemic circulation, providing steady blood levels, reducing fluctuation and improving compliance. The absorption rate and bioavailability vary depending on formulation; depot injections deliver a slow, sustained release compared to immediate-release formulations.

Distribution:
Leuprolide distributes widely in body tissues with a volume of distribution approximated in studies at about 28 L. It is a synthetic peptide analog of gonadotropin-releasing hormone (GnRH) and, as such, circulates primarily in the plasma with limited binding to plasma proteins. It penetrates the hypothalamus and pituitary gland efficiently to exert its pharmacologic actions. Crosses the placenta and is expected to be present in low concentrations in breast milk based on molecular size and peptide nature.

Metabolism:
Leuprolide is primarily metabolized by enzymatic hydrolysis in peripheral tissues and plasma, leading to smaller peptide fragments and amino acids that are inactive. It undergoes no significant metabolism via the cytochrome P450 enzyme system, lowering the risk of metabolic drug interactions. The metabolic breakdown occurs rapidly once leuprolide is released from its depot form. The pharmacologically active form is leuprolide acetate or leuprolide mesylate, depending on preparation.

Elimination:
The elimination half-life of leuprolide varies with formulation: immediate-release forms exhibit a half-life of about 3 hours, while depot formulations prolong effective drug action through slow absorption over several weeks to months. The metabolites and peptide fragments are eliminated mainly via renal excretion. Clearance is reduced in renal impairment but no dosage adjustment is generally necessary. Sustained-release forms maintain measurable plasma concentrations for multiple months post-injection. Steady-state is typically achieved with repeated dosing. Clinical studies demonstrate that steady suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) is sustained, confirming effective elimination and drug kinetics for ongoing hormonal blockade.

Dosage Forms

Available Dosage Forms:
- Intramuscular kit with varying depot doses: 7.5 mg monthly; 11.25 mg every 3 months; 22.5 mg every 3 months; 30 mg every 4 months; 45 mg every 6 months
- Intramuscular powder for injection, extended release: 3.75 mg monthly; 11.25 mg every 3 months; 22.5 mg every 3 months
- Subcutaneous emulsion: 42 mg every 6 months
- Subcutaneous kit: 1 mg/0.2 mL solution for injection
- Subcutaneous powder for injection, extended release: 7.5 mg monthly; 22.5 mg every 3 months; 30 mg every 4 months; 45 mg every 6 months
- Viadur implant: 65 mg subcutaneous implant providing 12 months drug release

Dosages for Adults and Adolescents:
- Endometriosis: 3.75 mg intramuscular monthly or 11.25 mg depot every 3 months, up to 6 months duration; hormone replacement therapy recommended to mitigate bone loss
- Prostate Cancer (Advanced):
* Eligard brand administered subcutaneously as 7.5 mg monthly, 22.5 mg every 3 months, 30 mg every 4 months, or 45 mg every 6 months
* Viadur implant subcutaneously once every 12 months
- Uterine Fibroids with Anemia: Leuprolide used with other medication for hematologic improvement

Specific Patient Populations:
- Pediatric (Central Precocious Puberty): children aged 2 years and older
* IM Injection dosing titrated by weight:
- ≤25 kg: 7.5 mg monthly
- >25 to 37.5 kg: 11.25 mg monthly
- >37.5 kg: 15 mg monthly
* 3-month depot: 11.25 mg or 30 mg IM every 3 months
* Subcutaneous long-acting (Fensolvi): 45 mg every 6 months
- Dose titration guided by hormonal levels and clinical response
- Therapy adjusted as patient grows, with hormone suppression monitoring
- Treatment discontinued at appropriate puberty age per physician discretion

Clinical dosing should always follow prescribing information and be tailored individually based on patient weight, indication, and response to therapy. Administration is by trained healthcare professionals or trained patients/caregivers in outpatient settings.

Mechanism Of Action

Leuprolide is a potent synthetic analog of gonadotropin-releasing hormone (GnRH), acting primarily as a GnRH agonist. Upon administration, it initially stimulates the pituitary GnRH receptors, leading to a transient increase in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. This surge briefly elevates gonadal steroid hormone (testosterone in men, estrogen in women) levels. However, continuous exposure to leuprolide results in downregulation and desensitization of GnRH receptors in the anterior pituitary gland, leading to profound suppression of LH and FSH secretion over days to weeks.

The decreased release of LH and FSH results in diminished production of gonadal steroids by the testes and ovaries, effectively inducing a reversible hypogonadism state. In men, this reduces testosterone levels to castrate ranges, useful in treating hormone-sensitive prostate cancer. In women, suppression of estrogen production reduces symptoms and progression of estrogen-dependent conditions such as endometriosis and uterine fibroids.

At the molecular level, leuprolide binds GnRH receptors, activating G-protein coupled receptor pathways and increasing intracellular calcium and cyclic AMP, initially stimulating gonadotropin release. Subsequent prolonged receptor occupancy triggers receptor internalization and downregulation, terminating the stimulatory signal. This biphasic pharmacodynamic effect underpins its usefulness in both stimulating and suppressing gonadotropin release according to dosing pattern.

Clinically, leuprolide’s mechanism allows for controlled suppression of reproductive hormone axes. Compared to GnRH antagonists, which block receptors immediately, leuprolide requires an induction period with an initial flare effect. This initial surge may exacerbate symptoms temporarily, necessitating concomitant androgen receptor blockers or other therapies in prostate cancer patients. Research supports long-term use for conditions requiring hormonal suppression, with efficacy attributable to sustained pituitary downregulation and consequent gonadal steroid deprivation.

Pharmacological Actions

Acts as a GnRH receptor agonist with eventual receptor desensitization
Suppresses pituitary secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH)
Leads to decreased gonadal steroidogenesis: testosterone in males, estrogen in females
Induces reversible medical castration or chemical menopause
Reduces hormone-dependent tumor growth in prostate cancer
Alleviates symptoms of endometriosis by suppressing estrogen production
Decreases growth and bleeding associated with uterine fibroids
Used in pediatric patients to halt premature sexual development in central precocious puberty
Provides controlled hormonal suppression with varied dosing intervals via depot/implant forms
Modifies hypothalamic-pituitary-gonadal axis dynamics
Initial transient stimulation followed by sustained suppression of gonadotropins
Used adjunctively in assisted reproductive technologies to prevent premature ovulation
Lacks significant cytochrome P450 metabolism, reducing drug interaction potential
Exerts systemic hormonal effects through central endocrine regulation
Modulates sex hormone-related physiological processes in various disease states

Therapeutic Or Clinical Uses

Treatment of advanced prostate cancer via androgen deprivation therapy
Management of central precocious puberty in children to delay early sexual maturation
Treatment of endometriosis to relieve pain and reduce endometrial lesions
Adjunct treatment to improve anemia secondary to uterine fibroids
Reduction of uterine fibroid size and symptoms prior to surgery
Hormonal control in assisted reproductive technologies (e.g., IVF protocols)
Off-label uses in breast cancer hormone therapy regimens
Suppression of pituitary gonadotropins in hormone-responsive tumors
Symptomatic management of hormone-dependent gynecological disorders
Preoperative hormonal preparation in uterine leiomyomata
Induction of chemical castration in gender dysphoria treatment protocols (off-label)
Management of hormone-related end-organ diseases requiring gonadal suppression
Therapeutic option for patients contraindicated for surgical orchiectomy or oophorectomy
Prevention of premature ovulation during ovulation induction treatments
Short-term use to facilitate other therapies requiring downregulated gonadal function

Side Or Adverse Effects

Injection site reactions: pain, redness, swelling, or oozing
Initial hormone flare symptoms including bone pain and worsening disease manifestations
Hot flashes, sweating, and vasomotor symptoms due to hypoestrogenism/hypogonadism
Decreased libido, erectile dysfunction, and testicular atrophy in males
Menstrual irregularities, vaginal dryness, and decreased fertility in females
Mood changes including irritability, depression, and agitation
Headache, dizziness, and general malaise
Gastrointestinal disturbances such as nausea, vomiting, diarrhea, or constipation
Breast tenderness or enlargement in both sexes
Acne, rash, itching, and seborrhea
Cold or flu-like symptoms including nasal congestion, sore throat, and cough
Bone density loss with prolonged use leading to increased fracture risk
Seizures or neurological symptoms in predisposed individuals
Pituitary gland dysfunction causing headaches, visual disturbances, or hormonal imbalances
Metabolic effects including elevated blood sugar and potential cardiovascular risks

Precautions

Use caution in patients with a history of depression, psychiatric disorders, or seizure disorders
Monitor bone mineral density during prolonged therapy, especially in female patients
Assess cardiovascular risk factors due to potential increased risk of heart attack or stroke
Use effective contraception during treatment due to teratogenic potential and risk of birth defects
Adjust dosing carefully in pediatric patients, monitoring hormonal suppression and growth
Closely monitor patients with pituitary or hypothalamic disorders
Avoid use in patients with unexplained abnormal vaginal bleeding until diagnosis confirmed
Careful monitoring for changes in mood or behavior due to neuropsychiatric effects
Beware of electrolyte imbalances; assess potassium and magnesium levels in high-risk patients
Consider interactions with other medications that prolong QT interval or affect cardiac conduction
Avoid abrupt discontinuation to prevent rebound hormonal effects
Use caution in patients with hematologic disorders or predisposition to thrombosis
Regularly monitor glucose levels in patients at risk for hyperglycemia or diabetes
Inform patients about potential initial symptom worsening (tumor flare or pubertal changes)
Counsel regarding possible effects on fertility and sexual function

Warnings

Initial worsening of symptoms due to hormonal surge can occur during first weeks of therapy
Risk of seizure, severe headache, vision changes, and neurological symptoms necessitating urgent evaluation
Potential for serious allergic reactions including anaphylaxis and severe skin reactions
Pregnancy is contraindicated due to known teratogenicity; effective contraception mandatory
Risk of pituitary apoplexy, especially in patients with existing pituitary adenomas
May cause significant bone loss with long-term use leading to osteoporosis and fractures
Possibility of increased cardiovascular events, including myocardial infarction and stroke
Monitor for signs of diabetes mellitus or worsening glycemic control
Use with caution in patients with prolonged QT interval or on QT-prolonging drugs
Not indicated for use in patients with unexplained vaginal bleeding until cause identified
Risk of severe mood and behavioral changes, require immediate medical consultation if observed
Injection site reactions may necessitate discontinuation in rare cases
Treatment may mask symptoms of disease progression or require careful clinical assessment
Children receiving treatment require monitoring for growth and development anomalies
Avoid concomitant use with other hormonal therapies unless specifically advised

Contraindication

Known hypersensitivity or allergy to leuprolide or other GnRH analogs (e.g., buserelin, goserelin, histrelin, nafarelin)
Pregnancy due to risk of fetal harm and teratogenicity
Unexplained abnormal vaginal bleeding not evaluated by a healthcare provider
Patients with pituitary gland tumors presenting with acute symptoms unless closely monitored
Women who are breastfeeding unless benefits outweigh potential risks
Concurrent use with drugs contraindicated due to additive cardiac risks without medical supervision
Severe psychiatric conditions that may be exacerbated by hormonal manipulation
Known severe renal impairment where close monitoring cannot be ensured
History of severe hypersensitivity reactions to injectable peptide medications
Patients at high risk for thromboembolic events without adequate prophylaxis

Drug Interactions

Co-administration with androgen receptor blockers may be used to manage tumor flare in prostate cancer but requires monitoring
Drugs known to prolong QT interval (e.g., certain antiarrhythmics, erythromycin, antipsychotics) may increase risk of cardiac arrhythmias
Concurrent use with other hormone therapies (estrogens, progestins, corticosteroids) may affect efficacy and side effect profile
Interactions with antiepileptic medications may require dose adjustments due to seizure risk
Possible increased effect or toxicity when combined with drugs affecting electrolyte balance such as diuretics
May alter pharmacodynamics of insulin and oral hypoglycemics, necessitating glucose monitoring
Concomitant use with immunosuppressants or chemotherapy agents can increase susceptibility to infections and toxicity
Interaction with antidepressants and other CNS-active medications may potentiate neuropsychiatric side effects
Use with caution when combined with medications for infections, asthma, hypertension, or mental illness due to reported serious heart problems
Potential additive risk of osteoporosis when used with corticosteroids or other bone-depleting agents
No significant cytochrome P450 mediated interactions observed, reducing metabolic interaction risk
Potential interference with laboratory tests measuring LH, FSH, and sex steroids impacting clinical monitoring
May reduce effectiveness of fertility treatments if used concurrently outside intended protocols
Additive effects with other GnRH analogs or antagonists contraindicated
Herbal supplements with hormonal activity may interfere with leuprolide therapy outcomes

Preparations Of The Drug

Camcevi: subcutaneous extended-release injection for prostate cancer
Eligard: subcutaneous depot injection available in multiple dosage strengths for 1 to 6 months release
Fensolvi: long-acting subcutaneous injection for central precocious puberty
Lupron Depot: intramuscular depot formulation for endometriosis, prostate cancer, and central precocious puberty
Lupron Depot-Ped: pediatric formulation for central precocious puberty
Viadur: 12-month subcutaneous implant for prostate cancer
Intramuscular powder for injection extended-release kits in doses including 3.75 mg, 7.5 mg, 11.25 mg, 22.5 mg, 30 mg, 45 mg
Subcutaneous powder for injection extended-release kits in similar dose ranges
Various monthly, quarterly, 4-month, 6-month depot and implant formulations to suit clinical needs
Preparations require reconstitution and proper handling by healthcare professionals
All depot formulations designed to provide consistent plasma leuprolide levels
Formulations differ in route, duration, and dosing to optimize therapy for specific indications
Storage guidelines require refrigeration and protection from freezing
Single-dose administration devices with caution to prevent needle reuse and contamination
Pharmaceutical preparation and administration tailored according to patient age, weight, and indication